KR20100049695A - 방출 조절 제형 - Google Patents

방출 조절 제형 Download PDF

Info

Publication number
KR20100049695A
KR20100049695A KR1020107008536A KR20107008536A KR20100049695A KR 20100049695 A KR20100049695 A KR 20100049695A KR 1020107008536 A KR1020107008536 A KR 1020107008536A KR 20107008536 A KR20107008536 A KR 20107008536A KR 20100049695 A KR20100049695 A KR 20100049695A
Authority
KR
South Korea
Prior art keywords
pharmaceutical formulation
core tablet
formulation
release
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107008536A
Other languages
English (en)
Korean (ko)
Inventor
이. 이츠하크 레너
베레드 로센-버거
오페르 아콰
모세 플래쉬너-바라크
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20100049695A publication Critical patent/KR20100049695A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B30—PRESSES
    • B30B—PRESSES IN GENERAL
    • B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/34—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses for coating articles, e.g. tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107008536A 2002-03-04 2003-03-03 방출 조절 제형 Ceased KR20100049695A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36182102P 2002-03-04 2002-03-04
US60/361,821 2002-03-04
US29161902A 2002-11-12 2002-11-12
US10/291,619 2002-11-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7013799A Division KR20050023235A (ko) 2002-03-04 2003-03-03 방출 조절 투여 형태

Publications (1)

Publication Number Publication Date
KR20100049695A true KR20100049695A (ko) 2010-05-12

Family

ID=27807664

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107008536A Ceased KR20100049695A (ko) 2002-03-04 2003-03-03 방출 조절 제형

Country Status (13)

Country Link
EP (1) EP1492508A4 (https=)
JP (1) JP2005524670A (https=)
KR (1) KR20100049695A (https=)
CN (1) CN1649569B (https=)
AU (2) AU2003217909C1 (https=)
BR (1) BR0308305A (https=)
CA (1) CA2477701A1 (https=)
EA (1) EA005866B1 (https=)
IL (1) IL163887A0 (https=)
MX (1) MXPA04008536A (https=)
NO (1) NO20044188L (https=)
NZ (1) NZ535083A (https=)
WO (1) WO2003075893A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
AU2003249478A1 (en) * 2002-07-19 2004-02-09 Ranbaxy Laboratories Limited Taste masked sumatriptan tablets and processes for their preparation
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
KR100801946B1 (ko) * 2002-11-12 2008-02-12 테바 파마슈티컬 인더스트리즈 리미티드 티자니딘의 협측 및 설하 전달용의 약학 조성물 및 제형과티자니딘의 설하 또는 협측 투여 방법
US7713455B2 (en) * 2003-11-14 2010-05-11 Sanwa Kagaku Kenkyusho Co., Ltd. Method of manufacturing a molding with a core
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
WO2005079811A1 (en) * 2004-02-19 2005-09-01 Teva Pharmaceutical Industries Ltd. Improved therapy using a combination of raloxifene and alendronate
KR100701409B1 (ko) 2004-11-26 2007-03-30 한국유나이티드제약 주식회사 호박산 수마트립탄을 함유하는 약제학적 조성물
JP2012500221A (ja) 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
CN110368371A (zh) * 2014-04-08 2019-10-25 越洋医药开发(广州)有限公司 一种新型控释片
JP6878417B2 (ja) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド 剤形およびそれらの使用
CN110604724A (zh) * 2019-10-22 2019-12-24 恒诚制药集团淮南有限公司 一种肠溶美沙拉秦缓释片剂及其制备方法
US12543731B2 (en) 2022-10-13 2026-02-10 Clarke Mosquito Control Products, Inc. Insecticidal tablet compositions
JP2024083720A (ja) * 2022-12-12 2024-06-24 パナソニックＩｐマネジメント株式会社 水処理用徐放性固形薬剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
JPS61243016A (ja) * 1985-04-19 1986-10-29 Katsumi Takada 柱状の有効成分含有部分をもつ錠剤
GB8514666D0 (en) * 1985-06-11 1985-07-10 Coopers Animal Health Agent delivery systems
JPS6253918A (ja) * 1985-09-02 1987-03-09 Katsumi Takada 柱状の有効成分含有部分を埋没させた錠剤
DE4431653C2 (de) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
JP3962108B2 (ja) * 1995-04-03 2007-08-22 中外製薬株式会社 スクラルファート含有製剤組成物
CA2184316A1 (en) * 1995-09-12 1997-03-13 Wei-Chi Liao Buccal delivery system for therapeutic agents
EP0931543B1 (de) * 1997-12-19 2002-03-20 MERCK PATENT GmbH Mehrschichttablette enthaltend probiotische Mikroorganismen wie z.B. Lactobacilli oder Bifidobakterien
KR100597331B1 (ko) * 1997-12-22 2006-07-10 쉐링 코포레이션 생체 이용률이 향상된 분자 분산액 조성물
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
AU2001271700A1 (en) * 2000-06-28 2002-01-08 Nitrosystems, Inc. Controlled release arginine formulations
CA2470495A1 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it

Also Published As

Publication number Publication date
IL163887A0 (en) 2005-12-18
AU2009200353A1 (en) 2009-02-19
EA005866B1 (ru) 2005-06-30
WO2003075893A1 (en) 2003-09-18
JP2005524670A (ja) 2005-08-18
MXPA04008536A (es) 2005-09-08
BR0308305A (pt) 2004-12-28
CN1649569B (zh) 2010-05-05
CA2477701A1 (en) 2003-09-18
EP1492508A1 (en) 2005-01-05
CN1649569A (zh) 2005-08-03
AU2003217909B2 (en) 2008-10-30
EP1492508A4 (en) 2009-05-06
EA200401097A1 (ru) 2005-04-28
NZ535083A (en) 2007-06-29
AU2003217909C1 (en) 2009-06-11
AU2003217909A1 (en) 2003-09-22
NO20044188L (no) 2004-12-03

Similar Documents

Publication Publication Date Title
US20040052843A1 (en) Controlled release dosage forms
KR100897837B1 (ko) 분말 또는 과립 물질의 압착된 환상체 내에 싸인 활성성분의 코어 정제를 갖는 제형과, 이의 제조 방법 및 툴링
RU2179017C2 (ru) Фармацевтическая композиция для контролируемого высвобождения активных веществ (варианты) и способ ее получения (варианты)
AU2009200353A1 (en) Controlled release dosage forms
KR20030023879A (ko) 알렌드로네이트 및/또는 기타 비스-포스포네이트의 지연형위 방출을 위한 조성물 및 제형
EP1019029B1 (en) Monolithic system containing one or more drugs, consisting of three layers with different release mechanisms
KR20070036797A (ko) 장용 코팅된 중심정을 갖는 제형
JP2015091830A (ja) 有機化合物のガレヌス製剤
KR20050023235A (ko) 방출 조절 투여 형태
ZA200407023B (en) Controlled release dosage forms
AU2002352613B2 (en) Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
JP2008507587A (ja) 腸溶性被覆されたコアー錠剤を有する投与形
ZA200405012B (en) Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of power or granular material, and process and tooling for producing it.

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000